Aug 5, 2026 04:14PM
Jun 15, 2026 06:30AM
Jun 15, 2026 06:30AM
May 6, 2026 04:18PM
Apr 2, 2026 07:30AM
Apr 2, 2026 07:30AM
Dec 16, 2025 12:18PM Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
Mar 20, 2025 04:22PM
Nov 6, 2024 04:06PM
Sep 23, 2024 07:31AM
Sep 23, 2024 07:30AM
Aug 7, 2024 04:17PM
Aug 1, 2024 07:31AM
Aug 1, 2024 07:30AM Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
Jul 11, 2024 10:30AM
Jul 10, 2024 07:30AM
Jul 10, 2024 07:30AM
May 8, 2024 04:06PM
May 2, 2024 07:32AM
May 2, 2024 07:31AM
Apr 1, 2024 07:30AM Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Mar 21, 2024 07:43AM
Nov 9, 2023 04:15PM
Jan 31, 2023 07:30AM
Jan 31, 2023 07:30AM
Jan 31, 2023 07:30AM
Jan 4, 2023 07:30AM
Jan 4, 2023 07:30AM Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
Nov 29, 2022 07:31AM
Nov 29, 2022 07:30AM
Nov 29, 2022 07:30AM
Sep 27, 2022 07:30AM
Sep 27, 2022 07:30AM
Dec 3, 2019 08:00AM
Nov 8, 2019 08:00AM Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 American College of Rheumatology Annual Meeting and the 2019 American Academy of Physical Medicine and Rehabilitation Annual
Sep 17, 2019 08:02AM
Sep 17, 2019 08:00AM
Sep 4, 2019 11:11AM
Sep 4, 2019 11:11AM
Sep 4, 2019 08:00AM
Jul 18, 2019 07:30AM
Jun 11, 2019 07:30AM Centrexion Therapeutics to Announce CNTX-4975 Trial Results at the European League Against Rheumatism’s (EULAR) 2019 Annual European Congress of Rheumatology
Jun 5, 2019 07:30AM
Apr 29, 2019 08:25AM
Mar 27, 2019 07:30AM
Mar 7, 2019 07:30AM
Dec 5, 2018 07:30AM

330,672 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All